Musa N. Karim

Rafiqui Shaheed Road
Karachi, SD 75510, Pakistan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 107 publications

Long-term impact of frailty on mortality and quality of life in mechanically ventilated acute myocardial infarction patients undergoing percutaneous coronary intervention.

Long-term impact of frailty on mortality and quality of life in mechanically ventilated acute myocardial infarction patients undergoing percutaneous coronary intervention.

Journal: JAR life

Published: May 12, 2026

Rapid Inflation-Deflation vs Pressure-Optimized Stenting During Primary PCI: The RAPID-POP Trial.

Rapid Inflation-Deflation vs Pressure-Optimized Stenting During Primary PCI: The RAPID-POP Trial.

Journal: JACC. Cardiovascular interventions

Published: March 27, 2026

Reply: RIVAWAR Trial Commentary: Rivaroxaban vs Warfarin in Acute Left Ventricular Thrombus Following Myocardial Infarction.

Reply: RIVAWAR Trial Commentary: Rivaroxaban vs Warfarin in Acute Left Ventricular Thrombus Following Myocardial Infarction.

Journal: JACC. Advances

Published: September 16, 2025

Clinical Outcomes of the Prospective Pakistan Registry of Echocardiographic Screening in Asymptomatic Pregnant Women.

Clinical Outcomes of the Prospective Pakistan Registry of Echocardiographic Screening in Asymptomatic Pregnant Women.

Journal: JACC. Advances

Published: August 20, 2025

Development and Validation of NICVD-NQ Score for Predicting Short-Term Outcomes After Primary PCI.

Development and Validation of NICVD-NQ Score for Predicting Short-Term Outcomes After Primary PCI.

Journal: Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions

Published: August 13, 2025

Twice-Daily Clopidogrel vs Ticagrelor to Reduce Short-Term Major Adverse Cardiovascular Events After Primary Percutaneous Coronary Intervention: The TADCLOT Trial.

Twice-Daily Clopidogrel vs Ticagrelor to Reduce Short-Term Major Adverse Cardiovascular Events After Primary Percutaneous Coronary Intervention: The TADCLOT Trial.

Journal: Journal of the American College of Cardiology

Published: August 03, 2025

Point-of-care ultrasound vs. routine transthoracic echocardiography for screening of cardiovascular disease in pregnant women.

Point-of-care ultrasound vs. routine transthoracic echocardiography for screening of cardiovascular disease in pregnant women.

Journal: European heart journal. Imaging methods and practice

Published: May 06, 2025

Prognosticating short-term outcomes in patients with STEMI-ACS and intra-procedural slow-flow/no-reflow phenomenon.

Prognosticating short-term outcomes in patients with STEMI-ACS and intra-procedural slow-flow/no-reflow phenomenon.

Journal: Herz

Published: April 18, 2025

Assessment of the prognostic performance of TIMI, PAMI, CADILLAC and GRACE scores for short-term major adverse cardiovascular events in patients undergoing emergent percutaneous revascularisation: a prospective observational study.

Assessment of the prognostic performance of TIMI, PAMI, CADILLAC and GRACE scores for short-term major adverse cardiovascular events in patients undergoing emergent percutaneous revascularisation: a prospective observational study.

Journal: BMJ open

Published: March 12, 2025

Rivaroxaban vs Warfarin in Acute Left Ventricular Thrombus Following Myocardial Infarction: RIVAWAR, An Open-Label RCT.

Rivaroxaban vs Warfarin in Acute Left Ventricular Thrombus Following Myocardial Infarction: RIVAWAR, An Open-Label RCT.

Journal: JACC. Advances

Published: March 07, 2025

Enhancing knowledge of hypertension among general practitioners in Pakistan through a Train-The-Trainer initiative.

Enhancing knowledge of hypertension among general practitioners in Pakistan through a Train-The-Trainer initiative.

Journal: PloS one

Published: December 29, 2024

Rationale and design of the TADCLOT trial: A double blind randomized controlled trial comparing twice a day clopidogrel vs ticagrelor in reducing major cardiac events in patients with acute STEMI undergoing primary percutaneous coronary intervention.

Rationale and design of the TADCLOT trial: A double blind randomized controlled trial comparing twice a day clopidogrel vs ticagrelor in reducing major cardiac events in patients with acute STEMI undergoing primary percutaneous coronary intervention.

Journal: American heart journal

Published: December 14, 2024

Showing 1-12 of 107

Last Updated: 09/26/2026